{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:16:43Z","timestamp":1788445003463,"version":"build-2803163510"},"reference-count":28,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"unspecified","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Dr Abidi Pharmaceuticals","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,8,7]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Hypertrophic cardiomyopathy (HCM) is a genetic cardiovascular disorder affecting approximately 1 in 200 to 1 in 500 adults, with nearly 70% exhibiting the obstructive phenotype Hypertrophic Obstructive Cardiomyopathy (HOCM). Randomised trials have demonstrated the efficacy of mavacamten, a first-in-class cardiac myosin inhibitor which significantly reduced outflow tract gradients and improved symptoms, exercise capacity and quality of life in the HOCM cases. Despite these findings, prospective real-world data on its safety and effectiveness remain limited, particularly in non-Western populations and further evidence from routine clinical practice is needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>PERSIA-HOCM is a prospective, multicentre, observational study to be conducted at 19 cardiovascular referral centres in Iran. Adults aged 18 years or older with symptomatic obstructive HCM, defined as New York Heart Association (NYHA) class II to IV and a left ventricular outflow tract (LVOT) gradient of at least 50 mm Hg at rest or with provocation, who are prescribed mavacamten, will be enrolled. Key exclusions include left ventricular ejection fraction below 55%, non-obstructive phenotype and lack of consent. Participants will be followed for 1 year at 4-week intervals. Data collection will include symptoms, NYHA class, vital signs, echocardiographic parameters (including outflow gradients and ejection fraction), mavacamten dosing and adjustments and concomitant therapies. Echocardiography will be performed at weeks 4, 8, 12 and 24. Safety will be assessed using a predefined adverse event framework that includes mortality, hospitalisations and major clinical events. At weeks 12 and 48, cardiac troponin, N-terminal pro B-type natriuretic peptide and quality of life will be assessed. Primary endpoints will be safety, change in the NYHA class, resting and provoked LVOT gradient, quality of life, cardiac biomarkers and left ventricular ejection fraction. Secondary endpoints will include cardiac magnetic resonance imaging parameters for cardiac fibrosis, peak oxygen intake and genotype-based outcome. Analyses will be performed using R V.4.5.1, employing descriptive statistics, paired sample t tests and McNemar\u2019s test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval was obtained from the Research Ethics Committee of Rajaie Cardiovascular, Medical and Research Institute\/Iran National Committee for Ethics in Biomedical Research (Code: IR.RHC.REC.1404.210). Written informed consent will be required and filled by the patients. Considering full data confidentiality, analysis reports will be public every 6 months. Findings will be disseminated through peer-reviewed publications and scientific conferences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-124273","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:45:27Z","timestamp":1788443127000},"page":"e124273","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective evaluation of real-world safety, symptoms improvement and adherence to mavacamten among Iranian patients with hypertrophic obstructive cardiomyopathy (PERSIA-HOCM): protocol of a multicentre observational study"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4322-0236","authenticated-orcid":false,"given":"Amirhossein","family":"Ghaseminejad-Raeini","sequence":"first","affiliation":[{"name":"Cardiovascular Epidemiology Research Center, Rajaie Cardiovascular Institute, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amin","family":"Karimi","sequence":"additional","affiliation":[{"name":"School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Shirinezhad","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Research Center, Rajaie Cardiovascular Institute, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadamin","family":"Aslani","sequence":"additional","affiliation":[{"name":"Vascular Disease and Thrombosis Research Center, Rajaie Cardiovascular Institute, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirali","family":"Soheili","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Center, Rajaie Cardiovascular Institute, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ghaderi","sequence":"additional","affiliation":[{"name":"Cardiovascular Imaging Research Center, Rajaie Cardiovascular Institute, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Haghjoo","sequence":"additional","affiliation":[{"name":"Cardiac Electrophysiology Research Center, Rajaie Cardiovascular Institute, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hooman","family":"Bakhshandeh","sequence":"additional","affiliation":[{"name":"Cardiovascular Epidemiology Research Center, Rajaie Cardiovascular Institute, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6067-040X","authenticated-orcid":false,"given":"Nasim","family":"Naderi","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Center, Rajaie Cardiovascular Institute, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"2026090306452172000_16.9.e124273.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.12.002"},{"key":"2026090306452172000_16.9.e124273.2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001250"},{"key":"2026090306452172000_16.9.e124273.3","doi-asserted-by":"crossref","first-page":"100073","DOI":"10.1016\/j.medp.2025.100073","article-title":"Hypertrophic cardiomyopathy: current understanding and emerging therapeutics","volume":"2","author":"Dai","year":"2025","journal-title":"Medicine Plus"},{"key":"2026090306452172000_16.9.e124273.4","doi-asserted-by":"crossref","DOI":"10.1186\/s44348-025-00050-9","article-title":"Current and emerging medical and surgical therapy in hypertrophic cardiomyopathy","volume":"33","author":"Kim","year":"2025","journal-title":"J Cardiovasc Imaging"},{"key":"2026090306452172000_16.9.e124273.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.12.002"},{"key":"2026090306452172000_16.9.e124273.6","first-page":"805","article-title":"The diagnosis and treatment of hypertrophic cardiomyopathy","volume":"121","author":"M\u00f6bius-Winkler","year":"2024","journal-title":"Dtsch Arztebl Int"},{"key":"2026090306452172000_16.9.e124273.7","doi-asserted-by":"crossref","DOI":"10.15420\/cfr.2025.08","article-title":"Emerging pharmacological and invasive therapies for hypertrophic cardiomyopathy with obstructive physiology","volume":"11","author":"Li-Wen Chu","year":"2025","journal-title":"Card Fail Rev"},{"key":"2026090306452172000_16.9.e124273.8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.309348"},{"key":"2026090306452172000_16.9.e124273.9","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.036387","article-title":"Procedural volume and outcomes after septal reduction therapies in hypertrophic obstructive cardiomyopathy","volume":"13","author":"Patel","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026090306452172000_16.9.e124273.10","doi-asserted-by":"crossref","first-page":"8594","DOI":"10.3390\/jcm14238594","article-title":"Mavacamten for obstructive hypertrophic cardiomyopathy: targeting sarcomeric hypercontractility with demonstrated long-term safety and efficacy\u2014a narrative review","volume":"14","author":"Mansour","year":"2025","journal-title":"JCM"},{"key":"2026090306452172000_16.9.e124273.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31792-X"},{"key":"2026090306452172000_16.9.e124273.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.04.048"},{"key":"2026090306452172000_16.9.e124273.13","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.012441","article-title":"Mavacamten: real-world experience from 22 months of the Risk Evaluation and Mitigation Strategy (REMS) program","volume":"18","author":"Desai","year":"2025","journal-title":"Circ Heart Fail"},{"key":"2026090306452172000_16.9.e124273.14","article-title":"Stop dreaming: mavacamten REMS data are here","volume":"18","author":"Masri","year":"2025","journal-title":"Circ: Heart Failure"},{"key":"2026090306452172000_16.9.e124273.15","doi-asserted-by":"crossref","DOI":"10.1007\/s11886-025-02316-6","article-title":"Mavacamten in the treatment of obstructive hypertrophic cardiomyopathy: from pathophysiology to real world data","volume":"27","author":"Panichella","year":"2025","journal-title":"Curr Cardiol Rep"},{"key":"2026090306452172000_16.9.e124273.16","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.042488","article-title":"Characteristics and outcomes of mavacamten use in 2440 patients with obstructive hypertrophic cardiomyopathy","volume":"14","author":"Mahana","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"2026090306452172000_16.9.e124273.17","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.044537","article-title":"Real-world observations in patients with obstructive hypertrophic cardiomyopathy treated with mavacamten: evidence of favorable disease modification","volume":"14","author":"Desai","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"2026090306452172000_16.9.e124273.18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4070\/kcj.2024.0443","article-title":"Real-world experience of mavacamten for patients with obstructive hypertrophic cardiomyopathy in South Korea: a prospective multi-center observational study","volume":"55","author":"Lim","year":"2025","journal-title":"Korean Circ J"},{"key":"2026090306452172000_16.9.e124273.19","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.124.017185","article-title":"Serial changes in ventricular strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: insights from the VALOR-HCM trial","volume":"17","author":"Desai","year":"2024","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026090306452172000_16.9.e124273.20","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1161\/CIRCULATIONAHA.124.072445","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 128 results from VALOR-HCM","volume":"151","author":"Desai","year":"2025","journal-title":"Circulation"},{"key":"2026090306452172000_16.9.e124273.21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5812\/cardiovascmed.4186","article-title":"Development and validation of the first Iranian questionnaire to assess quality of life in patients with heart failure: IHF-QoL","volume":"1","author":"Naderi","year":"2012","journal-title":"Res Cardiovasc Med"},{"key":"2026090306452172000_16.9.e124273.22","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14193"},{"key":"2026090306452172000_16.9.e124273.23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.66224\/ijbd.18.4.24","article-title":"Assessment of medication adherence and its relationship with disease uncertainty and socioeconomic factors in patients with breast cancer","volume":"18","author":"Dehesh","year":"2026","journal-title":"Iran J of Breast Dis"},{"key":"2026090306452172000_16.9.e124273.24","doi-asserted-by":"crossref","DOI":"10.31083\/RCM47341","article-title":"Targeting the sarcomere: myosin inhibitors as the revolutionary game changer in hypertrophic cardiomyopathy","volume":"27","author":"Sedaghat-Hamedani","year":"2026","journal-title":"Rev Cardiovasc Med"},{"key":"2026090306452172000_16.9.e124273.25","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad637"},{"key":"2026090306452172000_16.9.e124273.26","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14238594","article-title":"Mavacamten for obstructive hypertrophic cardiomyopathy: targeting sarcomeric hypercontractility with demonstrated long-term safety and efficacy\u2014a narrative review","volume":"14","author":"Mansour","year":"2025","journal-title":"J Clin Med"},{"key":"2026090306452172000_16.9.e124273.27","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"The Lancet"},{"key":"2026090306452172000_16.9.e124273.28","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jcmg.2025.07.019","article-title":"Long-term favorable cardiac remodeling in obstructive hypertrophic cardiomyopathy patients treated with mavacamten for up to 128 weeks: insights from the VALOR-HCM trial","volume":"18","author":"Desai","year":"2025","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-124273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:45:32Z","timestamp":1788443132000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-124273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,3]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjopen-2026-124273"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-124273","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}